Navigation Links
Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
Date:10/10/2007

SYDNEY, Australia, Oct. 10 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it had raised A$50 million through a placement to Australian, U.S., Asian and European institutions and professional investors. The placement strengthens the company's balance sheet as Pharmaxis continues with a series of international Phase III trials and embarks on the expansion of its manufacturing operation in Sydney.

Pharmaxis will issue 12.8 million new fully paid ordinary shares at A$3.90 per share, an 8.9% discount to Pharmaxis' last closing price on 8 October and a 2.0% discount to the volume weighted average share price over the past 30 days. The shares to be issued will rank equally with existing ordinary shares in the capital of the company. Shares sold to U.S. institutions have not been registered under the Securities Act of 1933 and were placed under an exemption from the Act.

Settlement of the placement is scheduled to take place on 16 October 2007.

A share purchase plan will be offered to all Australian and New Zealand shareholders who hold shares as at 7.00pm on 11 October 2007 and will afford the opportunity to purchase up to $5,000 worth of fully paid ordinary shares at the placement price of A$3.90, without brokerage or transaction costs. The share purchase plan offer opens on 19 October and closes on 09 November 2007.

CONTACT:

Alan Robertson - Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Virginia Nicholls

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

About Pharmaxis

Pharmaxis (A
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Rogne Bioscience, a privately-held ... Area , has acquired a licence to anti-inflammatory ... company. The potent anti-inflammatory activity of the peptides was ... University of Oxford,s Sir William Dunn School ... raised over $1.5 million in seed financing, is developing ...
(Date:7/31/2014)... July 31, 2014 North Shore Towers, a ... partnered with GI Energy, one of the nation’s leading combined ... million upgrade of its 43-year-old CHP system. The original CHP ... an effort to extend the life of the plant, GI ... associated electrical and heat recovery equipment, while maintaining continuous operation ...
(Date:7/31/2014)... , July 31, 2014 Research and ... "Global Genomics Market 2014-2018" report to their offering. ... Genomics is the study of the genetic material or ... a strong basis for the discovery and development of ... diseases or health conditions. Genomics is supported by three ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... pre-registration period for the European REACH regulation (Registration, Evaluation, ... 1, 2008, SAFC Supply Solutions(R), a business segment of ... SIAL ), conducted extensive research into which products ... its capacity to supply the products deemed critical to ...
... Bulletin Board: ACEL) today reported that it has conducted ... Administration (FDA) to discuss the company,s planned submission of ... Application (NDA) for the treatment of unresectable malignant mesothelioma ... provided guidance to the company recommending that an additional ...
... Pa., Jan. 27 Encorium Group, Inc. (Nasdaq: ... contract research organization (CRO) that provides design, development, and ... many of the world,s leading pharmaceutical companies, today announced ... primarily consisting of an extension of a current U.S. ...
Cached Biology Technology:SAFC Adopts Targeted Approach to Reach Pre-Registration 2SAFC Adopts Targeted Approach to Reach Pre-Registration 3SAFC Adopts Targeted Approach to Reach Pre-Registration 4Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 2Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 3
(Date:8/1/2014)... Center for Neuroscience and Department of Psychology has ... Fellowship from the U.S. Department of Defense. The ... on learning and memory in Ranganath,s Dynamic Memory ... aims to connect neural oscillations, which are currently ... hippocampus, brain regions that are known to be ...
(Date:8/1/2014)... of phloem, the conductive tissue through which plants transport ... cylindrical cells are capped at one end by a ... which in turn form a network throughout a plant,s ... cells which play an important role in carbon sequestration, ... their differentiation," says Professor Yk Helariutta from the Institute ...
(Date:8/1/2014)... -- LiveScan Service Provider Binary Biometrics is pleased to welcome Kevin ... will improve its mobile service capabilities and add more daily appointments, which will ... service several new cities such as, but not limited to, Daytona ... Deltona , Edgewater , Holly ... Beach , Oak Hill , Orange City ...
Breaking Biology News(10 mins):Developmental regulation of important plant phloem components discovered 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3
... on the slogan “milk does a body good,?radiologists are ... agent in gastrointestinal imaging exams—with excellent results. The researchers ... the Radiological Society of North America (RSNA). , “We ... as we see with the commonly used contrast agent, ...
... of California, San Diego and Yale University have discovered ... bacterium sprayed on crops by organic farmers to reduce ... in laboratory animals. , Their discovery, detailed in ... the National Academy of Sciences, could pave the way ...
... Estimates of increased plant respiration in response to higher ... not taken into account plants' ability to adjust to ... Laboratory. , In a Perspectives paper published April 28 ... ORNL findings suggesting that about 9 percent more carbon ...
Cached Biology News:Got inexpensive contrast agent? Milk plays new role in imaging 2Bacterial protein shows promise in treating intestinal parasites 2Bacterial protein shows promise in treating intestinal parasites 3Plants' role in global warming re-examined 2
... design in ice/water bath This CLS ... created to easily match Cornings product ... please order under the old Sigma-Aldrich ... for assistance. ID clarifier: rack and ...
... The Yeast Oligo Microarray Kit (V2), ... to simultaneously characterize expression of many ... gene activity during important biological processes. ... representing 6,256 known ORFs from the ...
... Oligo Microarray Kit (V2), 22K is useful for ... response. Each microarray contains content derived from the ... Genomic Research (TIGR) and represents 21,500 genes. ... 1 x 3? glass slides each containing an ...
... LCMSsolution software offers an intuitive, ... instrument control, diverse data handling, ... requirements. Comprehensive functions include data ... data management in both standalone ...
Biology Products: